Diovan

Diovan is a brand name of valsartan, approved by the FDA in the following formulation(s):

DIOVAN (valsartan - tablet; oral)

• 
  Manufacturer: NOVARTIS
  
  Approval date: July 18, 2001
  
  Strength(s): 160MG, 320MG ^[RLD], 80MG
  


• 
  Manufacturer: NOVARTIS
  
  Approval date: August 14, 2002
  
  Strength(s): 40MG
  

Has a generic version of Diovan been approved?

No. There is currently no therapeutically equivalent version of Diovan available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Diovan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Acyl compounds
  Patent 5,399,578
  Issued: March 21, 1995
  Inventor(s): Buhlmayer; Peter & Ostermayer; Franz & Schmidlin; Tibur
  Assignee(s): Ciba-Geigy Corp
  Compounds of the formula ##STR1## in which R.sub.1 is an aliphatic hydrocarbon radical which is unsubstituted or substituted by halogen or hydroxyl, or a cycloaliphatic or araliphatic hydrocarbon radical; X.sub.1 is CO, SO.sub.2, or --O--C(.dbd.O)-- with the carbon atom of the carbonyl group being attached to the nitrogen atom shown in formula I; X.sub.2 is a divalent aliphatic hydrocarbon radical which is unsubstituted or substituted by hydroxyl, carboxyl, amino, guanidino or a cycloaliphatic or aromatic radical, or is a divalent cycloaliphatic hydrocarbon radical, it being possible for a carbon atom of the aliphatic hydrocarbon radical to be additionally bridged by a divalent aliphatic hydrocarbon radical; R.sub.2 is carboxyl which, if desired, is esterified or amidated, substituted or unsubstituted amino, formyl which, if desired, is acetalized, 1H-tetrazol-5-yl, pyridyl, hydroxyl which, if desired, is etherified, S(O).sub.m --R where m is 0, 1 or 2 and R is hydrogen or an aliphatic hydrocarbon radical, alkanoyl, unsubstituted or N-substituted sulfamoyl or PO.sub.n H.sub.2 where n is 2 or 3; X.sub.3 is a divalent aliphatic hydrocarbon; R.sub.3 is carboxyl, 5-tetrazolyl, SO.sub.3 H, PO.sub.2 H.sub.2, PO.sub.3 H.sub.2 or haloalkylsulfamoyl; and the rings A and B independently of one another are substituted or unsubstituted; in free form or in salt form, can be prepared in a manner known per se and can be used, for example, as medicament active ingredients.
  
  Patent expiration dates:
  
  
  • March 21, 2012
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
  
  
  
  • March 21, 2012
    
  
  
  
  • September 21, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
  Patent 5,972,990
  Issued: October 26, 1999
  Inventor(s): Pfeffer; Marc A. & Pfeffer; Janice M. & Braunwald; Eugene
  Assignee(s): Brigham and Women's Hospital, Inc.
  The invention involves a method for treating a human survivor of a heart attack and provides further improvement in survival following the heart attack by the early initiation and long-term administration of a renin-angiotensin system inhibitor, preferably an angiotensin converting enzyme inhibitor. The inhibitor may be used on its own, or in conjunction with other therapeutic compounds such as data blockers and thrombolytic agents. The preferred inhibitor is captopril.
  
  Patent expiration dates:
  
  
  • October 26, 2016
    
    ✓ 
    Patent use: USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
  
  
  
  • April 26, 2017
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Solid oral dosage forms of valsartan
  Patent 6,294,197
  Issued: September 25, 2001
  Inventor(s): Wagner; Robert Frank & Katakuse; Yoshimitsu & Taike; Takashi & Yamato; Fujiki & Kohlmeyer; Manfred
  Assignee(s): Novartis AG
  The present invention is concerned with solid dosage forms comprising a) valsartan and optionally HCTZ, and b) pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods.
  
  Patent expiration dates:
  
  
  • June 18, 2017
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
  
  
  
  • December 18, 2017
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 29, 2010 - TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE
  
  
  • May 29, 2011 - PEDIATRIC EXCLUSIVITY
  
  

See also...

• Diovan Consumer Information (Drugs.com)
• Diovan Consumer Information (Wolters Kluwer)
• Diovan Consumer Information (Cerner Multum)
• Diovan Advanced Consumer Information (Micromedex)
• Valsartan Consumer Information (Wolters Kluwer)
• Valsartan Consumer Information (Cerner Multum)
• Valsartan Advanced Consumer Information (Micromedex)
• Valsartan AHFS DI Monographs (ASHP)